2022
Immunity waning after COVID vaccine booster vs. infection—better than expected
Khoury J, Najjar-Debbiny R, Elemy A, Jabbour A, Haj J, Abu-Sini M, Yasin R, Amin M, Hellou E, Nasrallah N, Saffouri A, Hakim F. Immunity waning after COVID vaccine booster vs. infection—better than expected. Infectious Diseases 2022, 54: 828-831. PMID: 35796285, DOI: 10.1080/23744235.2022.2097304.Peer-Reviewed Original ResearchConceptsBooster doseSecond doseThird doseSecond boosterBNT162b2 mRNA COVID-19 vaccineMRNA COVID-19 vaccineCOVID-19 PCRIgG antibody titresBAU/mLCOVID-19 vaccineEMMS Nazareth HospitalVaccine boosterSuggestive symptomsMean titresNasopharyngeal swabsProspective studyAsymptomatic infectionDoses groupsAntibody titresBooster groupGeneral populationHigh titresDoseTitresDoses
2021
COVID-19 vaccine – Long term immune decline and breakthrough infections
Khoury J, Najjar-Debbiny R, Hanna A, Jabbour A, Abu Ahmad Y, Saffuri A, Abu-Sinni M, Shkeiri R, Elemy A, Hakim F. COVID-19 vaccine – Long term immune decline and breakthrough infections. Vaccine 2021, 39: 6984-6989. PMID: 34763949, PMCID: PMC8556595, DOI: 10.1016/j.vaccine.2021.10.038.Peer-Reviewed Original ResearchConceptsAntibody titersCOVID-19 vaccineBreakthrough infectionsSecond doseAntibody levelsPolymerase chain reactionBNT162b2 mRNA COVID-19 vaccineSARS-CoV-2 polymerase chain reactionMRNA COVID-19 vaccineStudy periodBreakthrough infection rateMedian antibody levelsMean antibody levelsLongitudinal prospective studyAntibody declineTiter elevationImmune declineProspective studyClinical indicationsMild casesHealthcare personnelInfection rateInfectionVaccinePeak levels